Safety and Efficacy Analysis of Ultrasound-guided Microwave Ablation for Pediatric Recurrent Aggressive Fibromatosis

Overview

Journal J Orthop Surg Res

Publisher Biomed Central

Specialty Orthopedics

Date 2025 Feb 12

PMID 39940026

Authors

Hongxia Zhang

Linya Lv

Xin Li

Shuting Huang

Zhenzhen Zhao

Xiangru Kong

Affiliations

Soon will be listed here.

Abstract

Background: The treatment of aggressive fibromatosis (AF) poses a challenge for physicians due to propensity for local recurrence and aggressive nature, with traditional surgical excision often resulting in recurrence. Ultrasound-guided ablation, offering minimal trauma and reusability, has emerged as a novel therapeutic option for invasive fibromas. We report our experience of microwave ablation (MWA) as a local and analgesic treatment for inoperable or recurring AF.

Methods: This study includes 8 patients who underwent percutaneous MWA of 10 AF between November 2021 and November 2023. All patients underwent pain assessment using a visual analog scale (VAS) and preoperative imaging. Patients received clinical and radiological follow-up at 6 months post-procedure, with pain-rating and adverse events being recorded. A long-term follow-up was achieved until 1 November 2024.

Results: In this study, the 10 tumors in 8 patients have a preoperative size ranging from 1.84 to 477.96 ml, with a mean of 71.90 ± 147.55 ml. Postoperatively, at 6 months, the lesion sizes ranged from 0 to 174.99 ml, with a mean of 24.97 ± 53.78 ml (P < 0.05). The mean volume reduction ratio (VRR) was 55.86% (range 15.48-100%), with an overall treatment effectiveness rate of 80% (8 out of 10). Long-term follow-up revealed 2 cases meeting complete response (CR) criteria, 4 cases achieving partial response (PR), and 2 cases meeting stable disease (SD) criteria. The average pre-treatment VAS score among the 8 patients was 6.38 (range 5-9), which decreased to 3.0 (range 0-6) after 1 month of treatment, demonstrating a significant average pain reduction of 3.38 (p < 0.05). The study reported an adverse reaction incidence of 12.5% (1/8) due to neural heat damage from ablation, with symptom improvement following supportive care.

Conclusion: MWA is an effective therapeutic option for the local treatment and for the analgesic management of AF.

References

Burtenshaw S, Cannell A, McAlister E, Siddique S, Kandel R, Blackstein M . Toward Observation as First-line Management in Abdominal Desmoid Tumors. Ann Surg Oncol. 2016; 23(7):2212-9. DOI: 10.1245/s10434-016-5159-6. View

Gebert C, Hardes J, Kersting C, August C, Supper H, Winkelmann W . Expression of beta-catenin and p53 are prognostic factors in deep aggressive fibromatosis. Histopathology. 2007; 50(4):491-7. DOI: 10.1111/j.1365-2559.2007.02619.x. View

Sporns P, Psychogios M, Blackham K, Zech C, Wildgruber M, Takes M . Ultrasonography-guided radiofrequency ablation of vascular malformations-The moving shot technique. Front Med (Lausanne). 2024; 10:1345904. PMC: 10811020. DOI: 10.3389/fmed.2023.1345904. View

Ghanouni P, Dobrotwir A, Bazzocchi A, Bucknor M, Bitton R, Rosenberg J . Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors: a retrospective multicenter study. Eur Radiol. 2016; 27(2):732-740. PMC: 5097700. DOI: 10.1007/s00330-016-4376-5. View

Gounder M, Thomas D, Tap W . Locally Aggressive Connective Tissue Tumors. J Clin Oncol. 2017; 36(2):202-209. PMC: 6804876. DOI: 10.1200/JCO.2017.75.8482. View

Spear M, Jennings L, Mankin H, Spiro I, Springfield D, Gebhardt M . Individualizing management of aggressive fibromatoses. Int J Radiat Oncol Biol Phys. 1998; 40(3):637-45. DOI: 10.1016/s0360-3016(97)00845-6. View

von Mehren M, Kane J, Bui M, Choy E, Connelly M, Dry S . NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021. J Natl Compr Canc Netw. 2020; 18(12):1604-1612. DOI: 10.6004/jnccn.2020.0058. View

Ning B, Jian N, Ma R . Clinical prognostic factors for pediatric extra-abdominal desmoid tumor: analyses of 66 patients at a single institution. World J Surg Oncol. 2018; 16(1):237. PMC: 6299634. DOI: 10.1186/s12957-018-1536-x. View

Wang Y, Wang W, Tang J . Ultrasound-guided high intensity focused ultrasound treatment for extra-abdominal desmoid tumours: preliminary results. Int J Hyperthermia. 2011; 27(7):648-53. DOI: 10.3109/02656736.2011.597047. View

10.

Ni Y, Huang G, Yang X, Ye X, Li X, Feng Q . Microwave ablation treatment for medically inoperable stage I non-small cell lung cancers: long-term results. Eur Radiol. 2022; 32(8):5616-5622. DOI: 10.1007/s00330-022-08615-8. View

11.

Merchant N, Lewis J, Woodruff J, Leung D, Brennan M . Extremity and trunk desmoid tumors: a multifactorial analysis of outcome. Cancer. 1999; 86(10):2045-52. View

12.

Chu K, Dupuy D . Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer. 2014; 14(3):199-208. DOI: 10.1038/nrc3672. View

13.

Martinez-Martinez A, Garcia-Espinosa J, Lainez Ramos-Bossini A, Ruiz Santiago F . Percutaneous Microwave Ablation of Desmoid Fibromatosis. Korean J Radiol. 2021; 22(6):944-950. PMC: 8154784. DOI: 10.3348/kjr.2020.0768. View

14.

Li L, Qiu X . Safety and Efficacy of Ultrasound-Guided Radiofrequency Ablation for Benign Nonfunctional Thyroid Nodules in Children: A Retrospective Study of 62 Patients with Over Four Years of Follow-Up. Thyroid. 2021; 32(5):525-535. DOI: 10.1089/thy.2021.0454. View

15.

Auloge P, Garnon J, Robinson J, Thenint M, Koch G, Caudrelier J . Percutaneous cryoablation for advanced and refractory extra-abdominal desmoid tumors. Int J Clin Oncol. 2021; 26(6):1147-1158. DOI: 10.1007/s10147-021-01887-y. View

16.

Gronchi A, Jones R . Treatment of Desmoid Tumors in 2019. JAMA Oncol. 2019; 5(4):567-568. DOI: 10.1001/jamaoncol.2018.6449. View

17.

Bouhamama A, Lame F, Mastier C, Cuinet M, Thibaut A, Beji H . Local Control and Analgesic Efficacy of Percutaneous Cryoablation for Desmoid Tumors. Cardiovasc Intervent Radiol. 2019; 43(1):110-119. DOI: 10.1007/s00270-019-02323-5. View

18.

Mullen J, DeLaney T, Kobayashi W, Szymonifka J, Yeap B, Chen Y . Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series. Ann Surg Oncol. 2012; 19(13):4028-35. DOI: 10.1245/s10434-012-2638-2. View

19.

Wu C, Amini-Nik S, Nik-Amini S, Nadesan P, Stanford W, Alman B . Aggressive fibromatosis (desmoid tumor) is derived from mesenchymal progenitor cells. Cancer Res. 2010; 70(19):7690-8. DOI: 10.1158/0008-5472.CAN-10-1656. View

20.

Jiang L, Liang C, Xie F, Zheng Y . Microwave ablation in solitary hepatocellular carcinoma within 3-5 cm requiring consideration. Hepatobiliary Surg Nutr. 2023; 12(4):622-624. PMC: 10432303. DOI: 10.21037/hbsn-23-332. View